Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency in patients with inoperable pancreatic malignancy (PANcreatic cancer Dietary Assessment (PanDA): a study protocol. Issue 5 (13th May 2021)

• Record Type: Journal Article
• Authors: Carnie, Lindsay E; Lamarca, Angela; Vaughan, Kate; Kapacee, Zainul Abedin; McCallum, Lynne; Backen, Alison; Barriuso, Jorge; McNamara, Mairéad G; Hubner, Richard A; Abraham, Marc; Valle, Juan W
• Is Part Of: BMJ open. Volume 11:Issue 5(2021)
• Publication Date: 2021-05-13
• Subjects: pancreatic disease -- gastrointestinal tumours -- nutritional support -- nutrition & dietetics; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2020-042067
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Pancreatic exocrine insufficiency (PEI) in patients with pancreatic malignancy is well documented in the literature and is known to negatively impact on overall survival and quality of life. A lack of consensus opinion remains on the optimal diagnostic test that can be adapted for use in a clinical setting for this cohort of patients. This study aims to better understand the prevalence of PEI and the most suitable diagnostic techniques in patients with advanced pancreatic malignancy. Methods and analysis: This prospective observational study will be carried out in patients with pancreatic malignancy (including adenocarcinoma and neuroendocrine neoplasms). Consecutive patients with inoperable pancreatic malignancy referred for consideration of first-line chemotherapy will be considered for eligibility. The study comprises three cohorts: demographic cohort (primary objective to prospectively investigate the prevalence of PEI in patients with inoperable pancreatic malignancy); sample size 50, diagnostic cohort (primary objective to design and evaluate an optimal diagnostic panel to detect PEI in patients with inoperable pancreatic malignancy); sample size 25 and follow-up cohort (primary objective to prospectively evaluate the proposed PEI diagnostic panel in a cohort of patients with inoperable pancreatic malignancy); sample size 50. The following is a summary of the protocol and methodology. Ethics and dissemination: Full ethical approval has been granted by the North West Greater Manchester East Research and Ethics Committee, reference: 17/NW/0597. This manuscript reflects the latest protocol V.8 approved 21 April 2020. Findings will be disseminated by presentation at national/international conferences, publication in peer-review journals and distribution via patient advocate groups. Trial registration number: 194255, NCT0361643 .